Encouraging Pathological Complete Response Rate from Neoadjuvant Chemotherapy with Albumin-Bound Paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Esophageal Squamous Carcinoma: Preliminary Outcome of a Retrospective Study

Encouraging Pathological Complete Response Rate from Neoadjuvant Chemotherapy with Albumin-Bound Paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Esophageal Squamous Carcinoma: Preliminary Outcome of a Retrospective Study

Wen Zhang,1,* Yong Li,2,* Liyan Xue,3 Dong Qu,4 Zhichao Jiang,1 Zhen Wang,2 Zhaoyang Yang,3 Aiping Zhou1 1Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing...

Full description

Bibliographic Details
Main Authors: Zhang W, Li Y, Xue L, Qu D, Jiang Z, Wang Z, Yang Z, Zhou A
Format: Article
Language:English
Published: Dove Medical Press 2021-03-01
Series:Cancer Management and Research
Subjects:
albumin-bound paclitaxel
cisplatin
capecitabine
esophageal squamous cell carcinoma
neoadjuvant chemotherapy
pathological complete response
Online Access:https://www.dovepress.com/encouraging-pathological-complete-response-rate-from-neoadjuvant-chemo-peer-reviewed-article-CMAR

Internet

https://www.dovepress.com/encouraging-pathological-complete-response-rate-from-neoadjuvant-chemo-peer-reviewed-article-CMAR

Similar Items